The manifestations of acute overdose would include nausea, vomiting, diarrhea, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for XELODA (capecitabine) overdose has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low–molecular-weight metabolite of the parent compound.

Single doses of XELODA (capecitabine) were not lethal to mice, rats, and monkeys at doses up to 2000 mg/kg (2.4, 4.8, and 9.6 times the recommended human daily dose on a mg/m² basis).

Dihydropyrimidine Dehydrogenase (DPD) Deficiency

XELODA (capecitabine) is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.

Severe Renal Impairment

XELODA (capecitabine) is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault]) [see Use In Specific Populations and CLINICAL PHARMACOLOGY].

Hypersensitivity

XELODA (capecitabine) is contraindicated in patients with known hypersensitivity to capecitabine or to any of its components. XELODA (capecitabine) is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil.

Last reviewed on RxList: 4/6/2011
This monograph has been modified to include the generic and brand name in many instances.